Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (zolmitriptan) in Healthy Male Volunteers
Study identifier:D1220C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open Label, Positron Emission Tomography (PET) Study with [11C]AZ10419369 to Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (zolmitriptan) in Healthy Male Volunteers
Medical condition
migraine
Phase
Phase 1
Healthy volunteers
Yes
Study drug
Rapimelt, [11C]AZ10419369
Sex
Male
Actual Enrollment
10
Study type
Interventional
Age
20 Years - 45 Years
Date
Study Start Date: 01 May 2010
Primary Completion Date: 01 Oct 2010
Study Completion Date: 01 Oct 2010
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 PET 1: baseline, PET 2: 10 mg Zomig® Rapimelt, PET 3: 5 mg ZOMIG® Rapimelt, PET 4 2.5 mg ZOMIG® Rapimelt | Drug: Rapimelt oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5. Other Name: ZOMIG® Drug: [11C]AZ10419369 solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt |
Contacts
Investigators
Principal Investigator
Stephen Kanes
AstraZeneca
